Bempegaldesleukin
id:
bempegaldesleukin-260-1016204
title:
Bempegaldesleukin
text:
Bempegaldesleukin is an experimental anti-cancer drug candidate. It is a PEGylated interleukin-2 (IL-2) acting as a CD122-preferential IL-2 pathway agonist designed to activate and proliferate CD8+ T cells and NK cells. It is being developed by Nektar Therapeutics. In August 2019 the FDA granted breakthrough therapy designation to bempegaldesleukin in combination with nivolumab for the treatment of advanced melanoma. It is in phase 3 clinical trials for melanoma and renal cell carcinoma.
brand slug:
wiki
category slug:
encyclopedia
description:
original url:
https://en.wikipedia.org/wiki/Bempegaldesleukin
date created:
date modified:
2023-08-16T00:43:10Z
main entity:
{"identifier":"Q68010523","url":"https://www.wikidata.org/entity/Q68010523"}
image:
fields total:
13
integrity:
13